Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasinghormone agonist triggering in high-risk oocyte donor cycles: A prospective, luteal-phase follow-up study

Fertility and Sterility

Volumn 93, Issue 7, 2010, Pages 2418-2420

  Bodri, Daniel ^a,b   Guillén, Juan José ^a   Trullenque, Marta ^a   Schwenn, Katja ^a   Esteve, Carolina ^a   Coll, Oriol ^a  

^a Clinica EUGIN   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

GnRH agonist triggering; GnRH antagonist; OHSS; Oocyte donation

Indexed keywords

CETRORELIX; CREATININE; FOLLITROPIN; TRIPTORELIN; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT PROTEIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CRYOPRESERVATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; HEMATOCRIT; HEMOCONCENTRATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LUTEAL PHASE; MAJOR CLINICAL STUDY; OOCYTE DONATION; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; ADOLESCENT; DONOR; DRUG EFFECT; DRUG POTENTIATION; METHODOLOGY; OVULATION INDUCTION; PHYSIOLOGY; RISK FACTOR; TIME;

ADOLESCENT; ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; MENOTROPINS; OOCYTE DONATION; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 77952555836     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.08.036     Document Type: Article

References (19)

1. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Re-prod 2006;21:1260-5.
2. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-re-leasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing invitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
3. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human cho-rionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oo-cyte donor cycles. Fertil Steril 2007;88:237-9.
4. Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonado-tropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril 2009;91: 365-71.
5. Hernandez ER, Gomez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hy-perstimulation syndrome in oocyte donation cycles. Fertil Steril 2009;91(Suppl):1358-61.
6. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006;86:1682-7.
7. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gyne-col Endocrinol 2009;25:60-6.
8. Bodri D, Guillen JJ, Polo A, Trullenque M, Esteve C, Coll O. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reprod Biomed Online 2008;17: 237-43.
9. van der Meer S, Gerris J, Joostens M, Tas B. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyper-stimulation syndrome. Hum Reprod 1993;8: 1628-31.
10. Chun E. Severe OHSS can be prevented in GnRH antagonist protocol using GnRH agonist to trigger ovulation [abstract P-149]. Fertil Steril 2005;84(Suppl 1):S301.
11. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreser-vation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod 2007;22:1348-52.
12. Navot D, Bergh PA, Laufer N. Ovarian hyperstimu-lation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58: 249-61.
13. Aboulghar MA, Mansour RT. Ovarian hyperstimu-lation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-89.
14. Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, et al. Dopamine agonist cabergoline reduces hemoconcen-tration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7.
15. Fabregues F, Balasch J, Manau D, Jimenez W, Arroyo V, Creus M, et al. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum Reprod 1998;13:2406-10.
16. Fabregues F, Balasch J, Gines P, Manau D, Jimenez W, Arroyo V, et al. Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. Am J Gastroenterol 1999;94:994-9.
17. Garcia-Velasco JA, Quea G, Piro M, Mayoral M, Ruiz M, Toribio M, et al. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 2009;92:222-5.
18. Giles J, Requena A, Garcia-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil Steril 2009; 91 (Suppl): 1366-9.
19. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J Assist Reprod Genet 2008;25:63-6.